Submission of Audited Financial Results for the quarter and year ended 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals (formerly Trimurthi Ltd) reported audited results for FY25 with total revenue surging to Rs 3,073.44 lakhs from Rs 453.12 lakhs in FY24, driven almost entirely by the newly expanded Pharma Business segment (Rs 2,950.95 lakhs vs Rs 14.51 lakhs prior). Profit after tax for the full year stood at Rs 8.45 lakhs versus Rs 7.04 lakhs in FY24. However, the company swung to deeply negative operating cash flow of Rs (1,358.45) lakhs (vs Rs (34.35) lakhs), mainly because trade receivables ballooned from Rs 1.34 lakhs to Rs 1,813.69 lakhs. Equity strengthened to Rs 1,753.93 lakhs after a Rs 185 lakh share capital raise and Rs 825 lakh from warrant issues, and the company carries no long-term debt. The auditor issued an unmodified (clean) opinion.
Sharp revenue scale-up signals a business transformation from the old securities/finance model into active pharma ingredients, but the steep jump in receivables and deeply negative operating cash flow mean most of the new sales are still uncollected — quality of earnings and working-capital risk warrant close watch despite the clean auditor opinion and improved headline profitability.